Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för N-hydroxy-7-(naphthalen-2-ylthio)heptanamide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

10 träffar

Bibliografisk träff 2021-01-07

Synergistic Anticancer Activity of <i>N</i>-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models.

Yun HJ, Kim HJ, Kim J, Kim SY, Chang HS, Park CS, Chang HJ, Park KC.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms22020536

Bibliografisk träff 2018-01-12

Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.

Lee YS, Kim SM, Kim BW, Chang HJ, Kim SY, Park CS, Park KC, Chang HS.

Neoplasia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.neo.2017.12.003

Bibliografisk träff 2017-01-28

Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.

Park KC, Kim SM, Jeon JY, Kim BW, Kim HK, Chang HJ, Lee YS, Kim SY, Choi SH, Park CS, Chang HS.

Neoplasia · research-article; journal article · DOI 10.1016/j.neo.2016.12.005

Bibliografisk träff 2015-12-23

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.

Kim SM, Park KC, Jeon JY, Kim BW, Kim HK, Chang HJ, Choi SH, Park CS, Chang HS.

BMC Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12885-015-1982-6

Bibliografisk träff 2015-01-23

The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.

Park KC, Heo JH, Jeon JY, Choi HJ, Jo AR, Kim SW, Kwon HJ, Hong SJ, Han KS.

BMC Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12885-014-1003-1

Bibliografisk träff 2014-09-05

A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells.

Park KC, Park JH, Jeon JY, Kim SY, Kim JM, Lim CY, Lee TH, Kim HK, Lee HG, Kim SM, Kwon HJ, Suh JS, Kim SW, Choi SH.

Br J Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bph.12590

Bibliografisk träff 2013-07-30

Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.

Takahashi N, Takeda K, Imai M.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2013.07.039

Bibliografisk träff 2010-12-15

Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.

Park KC, Kim SW, Park JH, Song EH, Yang JW, Chung HJ, Jung HJ, Suh JS, Kwon HJ, Choi SH.

Cancer Sci · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1349-7006.2010.01798.x

Bibliografisk träff 2009-03-01

N-hydroxy-7-(2-naphthylthio) heptanomide inhibits retinal and choroidal angiogenesis.

Kim JH, Kim JH, Oh M, Yu YS, Kim KW, Kwon HJ.

Mol Pharm · research support, non-u.s. gov't; journal article · DOI 10.1021/mp800178b

Bibliografisk träff 2007-03-02

Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.

Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC, Kwon HJ.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2007.02.126